NCT01324063View on ClinicalTrials.gov

A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)

PHASE3CompletedINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

November 30, 1986

Primary Completion Date

June 30, 1994

Conditions

Leukemia

Interventions

BIOLOGICAL

sargramostim

DRUG

amsacrine

DRUG

cytarabine

DRUG

daunorubicin hydrochloride

PROCEDURE

quality-of-life assessment

All Listed Sponsors

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK